Adaptive Biotechnologies (ADPT) Operating Expenses (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Operating Expenses data on file, last reported at $90.1 million in Q1 2026.

• Quarterly Operating Expenses rose 9.79% year-over-year to $90.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $342.1 million (up 2.77% YoY) and the FY2025 annual result came in at $334.1 million, down 2.17% from the prior year.
• Operating Expenses advanced to $90.1 million in Q1 2026 per ADPT's latest filing, from $84.5 million in the prior quarter.
• The five-year high for Operating Expenses was $116.9 million in Q4 2023, with the low at $79.1 million in Q3 2024.
• Average Operating Expenses over 5 years is $91.1 million, with a median of $90.5 million recorded in 2024.
• Year-over-year, Operating Expenses increased 27.55% in 2022 and slumped 30.43% in 2024.
• Adaptive Biotechnologies' Operating Expenses stood at $94.4 million in 2022, then increased by 23.8% to $116.9 million in 2023, then tumbled by 30.43% to $81.3 million in 2024, then grew by 3.88% to $84.5 million in 2025, then grew by 6.66% to $90.1 million in 2026.
• Business Quant data shows ADPT's Operating Expenses at $90.1 million in Q1 2026, $84.5 million in Q4 2025, and $83.7 million in Q3 2025.